Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 123.03M P/E - EPS this Y 67.60% Ern Qtrly Grth -
Income -42.12M Forward P/E -8.26 EPS next Y -4.90% 50D Avg Chg -1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 39.00%
Dividend N/A Price/Book 0.73 EPS next 5Y - 52W High Chg -45.00%
Recommedations 1.50 Quick Ratio 40.57 Shares Outstanding 25.65M 52W Low Chg 216.00%
Insider Own 14.27% ROA -25.87% Shares Float 16M Beta -
Inst Own 55.75% ROE -39.66% Shares Shorted/Prior 1.79M/663.46K Price 2.81
Gross Margin - Profit Margin - Avg. Volume 582,543 Target Price 58.33
Oper. Margin - Earnings Date May 13 Volume 112,276 Change -3.44%
About Talaris Therapeutics, Inc.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

TRML Chatroom

User Image intratio Posted - 1 day ago

$TRML Tourmaline Bio, Inc. Our advanced model deduces that this company s stock price offers gloomy outlooks for the near future and its stock price is in line with its long-term fundamentals

User Image 5layer Posted - 04/26/24

$TRML

User Image intratio Posted - 04/26/24

Tourmaline Bio, Inc. Our machine learning model computed this company s value will lose ground in the coming days and has a neutral long-term outlook $TRML

User Image bnags83 Posted - 04/24/24

$TRML should start seeing a recovery here. It’s still oversold and the price targets are 3x to 5x where we are today. Joined the party yesterday.

User Image intratio Posted - 04/24/24

Our engine lets us believe the price action of this stock will go south in the coming week and isn t going to offer a long-term opportunity $TRML

User Image godly1 Posted - 04/18/24

$TRML This stock is so oversold. We are at 16 with a target of 58 for the year by analysts.

User Image 5layer Posted - 04/17/24

$TRML 😭

User Image 5layer Posted - 04/15/24

$TRML

User Image jimmy_sam001 Posted - 04/11/24

$TRML Does $TRML have anything similar to ALPN ? They are both related to Immue system

User Image kbud Posted - 04/10/24

$TRML nothing here it’s been dead of last 3 weeks

User Image 5layer Posted - 04/09/24

$CRVO $trml a quiet chat with a company that's making similar moves.

User Image UnoffensiveName Posted - 04/06/24

$TRML

User Image 5layer Posted - 4 weeks ago

$TRML

User Image DailyStocksPicks Posted - 03/27/24

My Oversold pick #2 for today is $CABA This company is working on developing targeted cell therapies for autoimmune diseases. With FDA designations advancing its clinical trials and a solid financial strategy aimed at supporting its pipeline, analysts also see significant growth potential despite its current financial losses​​​​. $EXAI, $ALLO, $TRML, $HLVX https://youtu.be/7pOcCYEQIxM

User Image AlexPreda Posted - 03/26/24

$TRML Biggest mistake ever. Bought at 28$. Hope i can break even in the next couple of months...

User Image manageurmoney Posted - 03/26/24

$TRML, wait for volume

User Image manageurmoney Posted - 03/26/24

$DJT $TRML,

User Image DailyStocksPicks Posted - 03/26/24

Today's Oversold Stock #4: Cabaletta Bio ($CABA): Despite a recent stock price drop and an earnings miss, the company has achieved FDA Orphan Drug Designation for one of its treatments and shows promising progress in clinical trials. This suggests the stock might be oversold, with the market not fully recognizing Cabaletta Bio's potential in the biotech industry. $HLVX, $PRME, $TRML, $ALLO For More Details: https://youtu.be/JXc_UbBbj1o

User Image muskegbaymomentum Posted - 03/25/24

$TRML looking at entry soon.

User Image manageurmoney Posted - 03/25/24

$DJT, better gamble here $TRML, https://www.marketbeat.com/stocks/NASDAQ/TRML/institutional-ownership/

User Image manageurmoney Posted - 03/25/24

$TRML, inflows from funds is masive, insiders also substantial. Worth it

User Image benlevyesq Posted - 03/25/24

$TRML WTF goings on?

User Image cantare Posted - 03/25/24

$TRML pos

User Image Bigbossmann Posted - 03/24/24

$TRML Let’s see some recovery back to $32 this week.

User Image jimmy_sam001 Posted - 03/22/24

$TRML Feel like a short attack, the reason given for this drop is far-fetched

User Image ok2buy Posted - 03/22/24

$TRML Will now try to keep this under $25. This will fail./

User Image ok2buy Posted - 03/22/24

$TRML Pure market manipulation. Someone call the cops because retail investors got fleeced today./

User Image ok2buy Posted - 03/22/24

$TRML Still think $26 will happen. Way overdone. Watch the asks get pulled./

User Image UnoffensiveName Posted - 03/22/24

$TRML https://www.marketbeat.com/instant-alerts/nasdaq-trml-boost-price-target-2024-03-21/

User Image ok2buy Posted - 03/22/24

$TRML Pure market manipulation. Absolutely zero reason for this punishment./

Analyst Ratings
Truist Securities Buy Mar 25, 24
Jefferies Buy Mar 20, 24
HC Wainwright & Co. Buy Mar 20, 24
Jefferies Buy Dec 15, 23
Truist Securities Buy Nov 17, 23
Guggenheim Buy Oct 31, 23
Piper Sandler Overweight Oct 25, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kulkarni Sandeep Chidambar CEO CEO Nov 17 Buy 16.99 4,000 67,960 729,735 11/20/23
Thiara Parvinder Director Director Nov 17 Buy 17.31 1,000 17,310 83,782 11/20/23
Castelein Caley Director Director Oct 25 Buy 13.31 20,000 266,200 516,519 10/27/23
Kulkarni Sandeep Chidambar CEO CEO Oct 24 Buy 11.47 9,650 110,686 725,735 10/26/23
KANTOFF AARON Director Director Oct 24 Buy 11.86 7,500 88,950 45,391 10/26/23
Thiara Parvinder Director Director Oct 24 Buy 11.39 7,000 79,730 82,782 10/26/23
Ildstad Suzanne Director Director Jun 12 Sell 2.55 44,020 112,251 3,771,392 06/14/23
Ildstad Suzanne Director Director Jun 07 Sell 2.44 141,062 344,191 3,815,412 06/09/23
Ildstad Suzanne Director Director Jun 05 Sell 2.52 33,390 84,143 2,756,474 06/07/23
Ildstad Suzanne Director Director Apr 21 Sell 2.3481 15,004 35,231 2,821,395 04/25/23
Ildstad Suzanne Director Director Mar 01 Sell 2.05 29 59 3,071,366 04/07/23
Ildstad Suzanne Director Director Feb 21 Sell 2.0529 3,500 7,185 3,071,395 04/07/23
Ildstad Suzanne Director Director Feb 16 Sell 2.05 6,551 13,430 3,074,895 04/07/23
Ildstad Suzanne Chief Scientific Off.. Chief Scientific Officer Aug 22 Sell 2.80 525,000 1,470,000 3,081,446 08/23/22
Requadt Scott Chief Executive Offi.. Chief Executive Officer Jul 29 Buy 4.25 39,382 167,374 508,680 08/02/22
Requadt Scott Chief Executive Offi.. Chief Executive Officer Jul 26 Buy 4.25 8,618 36,626 469,298 07/28/22
Requadt Scott Chief Executive Offi.. Chief Executive Officer Jul 22 Buy 3.7497 9,444 35,412 460,680 07/26/22
Nader Francois Director Director Jul 19 Buy 3.62 138,500 501,370 138,500 07/25/22